Refaat H Abdelmoety
Overview
Explore the profile of Refaat H Abdelmoety including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
12
Followers
0
Related Specialty
Related Specialty
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdelfatah R, Abdelmomen E, Abdelaleem E, Abdelmoety R, Emam A
BMC Chem
. 2025 Jan;
19(1):7.
PMID: 39773302
Co-administration of COVID-19 RNA polymerase inhibitors, remdesivir and favipiravir, has synergistic benefits. Together they reduce viral load and inflammation more effectively than either drug used alone. Corticosteroids like dexamethasone are...
2.
Abdelfatah R, Abdelaleem E, Abdelmomen E, Abdelmoety R, Emam A
J Sep Sci
. 2022 Aug;
45(20):3800-3810.
PMID: 35948316
Favipiravir and Meropenem have been concurrently used as directly acting antiviral and antibiotic agents for the treatment of coronavirus disease in human plasma. Accurate and specific reversed phase ultra-performance liquid...
3.
Emam A, Abdelaleem E, Abdelmomen E, Abdelmoety R, Abdelfatah R
Microchem J
. 2022 May;
179:107580.
PMID: 35582001
Innovative therapeutic protocols to the rapidly spreading coronavirus disease (COVID19) epidemic is highly required all across the world. As demonstrated by clinical studies, Favipiravir (FVP) and Remdesivir (REM) are new...